Impella Supported OPCABG

Running, not enrolling

Conditions studied: Ischemic Cardiomyopathy

In brief

The present study introduces a novel approach to coronary revascularization through the use of a short term minimally-invasive left ventricular assist device (LVAD) to minimize myocardial injury and eliminate low output state during the perioperative period

Key facts

Study ID

NCT04339452

Run by

Lucian Archambault Durham III

People needed

30

Starts

2022-05-11

Expected to finish

2026-03-01

Last updated by the study team

2025-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old
• Ejection fraction ≤ 35%
• Symptomatic three vessel Coronary Artery Disease with target vessels that are amenable to bypass (as determined by the operating surgeon) or Left main disease
• Adequate Distal target caliber (as determined by the PI or operating surgeon)

You may not qualify if…

• Exclusion criteria will include the existing contraindications to either Impella therapy or OPCABG revascularization:
• Patients with structural heart disease requiring cardiopulmonary bypass
• Patients with cardiogenic shock who require a period of short-term mechanical circulatory support
• Patients with mechanical aortic valve
• Patients with previous median sternotomy
• Patients with evidence of non-viability on preoperative cardiac MRI or CT scan
• Insufficient conduit
• BMI over 50
• Suspected or known pregnancy

Where it is running

• The Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.